CE / CME
In this video roundtable activity, Christoph U. Correll, MD; Leslie Citrome, MD, MPH; and Amber Hoberg, PMHNP, discuss recently published articles of interest in tardive dyskinesia care.
Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit
Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit
Social Workers: 1.00 ASWB ACE CE Credit
Pharmacists: 1.00 contact hour (0.1 CEUs)
Psychologists: 1.00 APA CE Credit
Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™
Released: October 19, 2022
Expiration: October 18, 2023
Share
Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
Amber Hoberg, PMHNP-BC
Morningstar Family Medicine PLLC
Baptist Healthcare System
San Antonio, Texas
Provided by Clinical Care Options, LLC
Supported by educational grants from
Neurocrine Biosciences, Inc.
Teva Pharmaceuticals
This activity is intended for psychiatrists, nurse practitioners, physician associates/physician assistants, nurses, pharmacists, psychologists, and social workers.
The goal of this activity is to improve the knowledge, competence, and performance of healthcare professionals to individualize the therapeutic management of patients with tardive dyskinesia.
Upon completion of this activity, participants should be able to:
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York
Leslie Citrome, MD, MPH: consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona; speaker: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, Medscape, NACCME, NEI, Vindico; stocks/stock options: Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, Pfizer, Reviva.
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
Christoph U. Correll, MD: consultant/advisor: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, Intra-Cellular Therapies, Janssen/Johnson & Johnson, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sun Pharma, Sunovion, Supernus, Takeda, Teva, Viatris; expert testimony: Janssen, Otsuka; data and safety monitoring board: Lundbeck, Relmada, Reviva, Rovi, Supernus, Teva; grant support: Janssen, Takeda; stock options: Cardio Diagnostics, Mindpax, LB Pharma, Quantic.
Amber Hoberg, PMHNP-BC
Morningstar Family Medicine PLLC
Baptist Healthcare System
San Antonio, Texas
Amber Hoberg, PMHNP: consultant/advisor/speaker: Acadia, Avanir, BioXcel, Intra-Cellular Therapies, Neurocrine, Teva.
Staff
Stephanie Filice, LICSW
Stephanie Filice, LICSW, has no relevant financial relationships to disclose.
Raquel Gaerlan,
Director, Scientific Services
Raquel Gaerlan has no relevant financial relationships to disclose.
Gabrielle Giacona,
Associate Scientific Director
Gabrielle Giacona: stock/stock options: AstraZeneca, Moderna, Teva.
Lisa Phipps, PharmD, PhD
Director, Science and Strategy, Neuroscience
Lisa Phipps, PharmD, PhD, has no relevant financial relationships to disclose.
Dace Svikis, PhD
Professor
Department of Psychology
Virginia Commonwealth University
Richmond, Virginia
Dace S. Svikis, PhD, has no relevant financial relationships to disclose.
Amanda Zimmerman, PA-C
West Forsyth Pain Management
Winston Salem, North Carolina
Amanda Zimmerman, PA-C: researcher: Biodelivery Sciences International.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-260-H01-P.
Type of Activity: Knowledge
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
This activity offers 1.0 continuing education credit for psychologists.
As a Jointly Accredited Organization, Clinical Care Options, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 clinical continuing education credits.
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for maximum of 1.0 hour of AAPA Category 1 CME credit. Approval is valid until October 17, 2023. PAs should only claim commensurate with the extent of their participation.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 19, 2022, through October 18, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Program Medium
This program has been made available online.